For years, women in remote Kimberley communities faced an impossible choice: travel hundreds of kilometers for cervical screening or go without. Now, research from the University of Notre Dame Australia is changing that reality.
A study published in The Lancet Public Health shows that bringing cervical screening directly to women’s doorsteps is dramatically improving access to health care in some of Australia’s most isolated regions.
Led by Dr. Aime Powell, Professor Jim Codde, and Associate Professor Katrina Spilsbury from Notre Dame’s Institute for Health Research, the national team partnered with local experts and services to trial a new model—one where health care travels to women, rather than the other way around.
In six Kimberley communities, researchers co-designed a culturally respectful program combining self-collection, immediate HPV testing, and same-day specialist follow-up. Delivered through WA Country Health Service outreach teams, the initiative ensured care was accessible, timely, and trusted.
The impact was significant. Nearly 110 women participated, reaching 64% of the region’s annual screening target in just four months. Almost all participants (99%) said they would recommend the program, citing privacy, convenience, and the reassurance of same-day results.
“I was very happy to have all tests and procedures done in one day. I would have been anxious if I had to wait. It’s about time remote communities had proper access to health care,” one participant said.
Researchers emphasize that the program’s success underscores the value of community-led design.
“When we design health care with communities, prioritize cultural safety, and ensure Aboriginal leadership guides the process, incredible things happen,” said Dr. Powell.
The study presents a promising model for improving health equity across Australia and aligns with the National Strategy for the Elimination of Cervical Cancer.
READ MORE
Low Cervical Cancer Screening Rates Drive Higher Deaths in Rural Areas
Self-Sampling Kits During GP Visits Boost Cervical Cancer Screening Rates
Canadian Approval for Pembrolizumab Combo in Cervical Cancer
